

Press Release

**Disclosure of total number of voting rights and number of shares in the capital at November 30<sup>th</sup>, 2016**

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France, December 9<sup>th</sup> 2016

Total number of shares	<b>10,084,334</b>
Number of real voting rights* (excluding treasury shares)	<b>10,053,223</b>
Theoretical number of voting rights* (including treasury shares**)	<b>10,067,313</b>

(\* ) Class B and E preference shares are non-voting

(\*\* ) pursuant to article 223-11 of the AMF’s General Regulations



**About Median Technologies:** Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors

worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. Median has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. ISIN: FR0011049824– ticker: ALMDT The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: [www.mediantechologies.com](http://www.mediantechologies.com)

***“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”***



**Contacts**

<p><b>Median Technologies</b> Fredrik Brag, CEO +33 4 92 90 65 82 <a href="mailto:fredrik.brag@mediantechnologies.com">fredrik.brag@mediantechnologies.com</a></p>	<p><b>Press</b> <b>ALIZE RP</b> Caroline Carmagnol + 33 1 44 54 36 66 <a href="mailto:median@alizerp.com">median@alizerp.com</a></p>	<p><b>Investors</b> <b>ACTIFIN</b> Ghislaine Gasparetto <a href="mailto:gasparetto@actifin.fr">gasparetto@actifin.fr</a> +33 1 56 88 11 11</p>
--	--	--